Rachelle Salunga
Medical-Surgical · Pasadena, CANPI 1801369251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,439 and has fallen 92.4% since, to $185 in 2025. Among medical-surgical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$691
- Novartis$278
- Merck$255
- Astellas Pharma US Inc$246
- Amgen$232
- Johnson & Johnson$232
- plus $3K from 34 others
What the payments were for
- Food & beverage$4,19394%
- Education$2716%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $691 |
| Novartis | 15 | $278 |
| Merck | 14 | $255 |
| Astellas Pharma US Inc | 11 | $246 |
| Amgen | 7 | $232 |
| Johnson & Johnson | 7 | $232 |
| E.r. Squibb & Sons, L.L.C. | 9 | $226 |
| Daiichi Sankyo Inc. | 4 | $173 |
| Bayer | 8 | $165 |
| Seagen Inc. | 3 | $140 |
| Incyte Corporation | 9 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $126 |
| Novo Nordisk | 1 | $124 |
| Karyopharm Therapeutics Inc. | 3 | $122 |
| Pfizer | 6 | $106 |
| AbbVie | 5 | $102 |
| Lilly USA, LLC | 4 | $93 |
| Bristol Myers Squibb | 4 | $91 |
| Taiho Oncology, Inc. | 3 | $80 |
| Myovant Sciences Inc. | 3 | $77 |
| AVEO Pharmaceuticals, Inc. | 3 | $75 |
| Sanofi | 4 | $75 |
| Jazz Pharmaceuticals Inc. | 3 | $74 |
| EMD Serono, Inc. | 3 | $59 |
| GSK | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Genentech USA, Inc. | 2 | $46 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Dova Pharmaceuticals | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Boehringer Ingelheim | 2 | $29 |
| Blueprint Medicines Corporation | 1 | $29 |
| EUSA Pharma (US) LLC | 2 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $23 |
| Acrotech Biopharma Inc. | 1 | $22 |
| Exelixis Inc. | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Secura Bio, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,464 in reported general payments places this provider in the 95th percentile of 21 medical-surgical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,361 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $2,264 |
| SsdSilver Sulfadiazine | 33 | $1,250 |
| Anastrozole | 39 | $948 |
| Nystatin | 15 | $547 |
| Tamoxifen Citrate | 14 | $374 |
| Lidocaine Hcl ViscousLidocaine Hcl | 22 | $374 |
| Letrozole | 30 | $280 |
| Hydrocortisone | 14 | $202 |
| Tamsulosin Hcl | 17 | $181 |
| Ondansetron Hcl | 14 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $6,36111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 medical-surgical providers in California.
Other medical-surgical in Pasadena
- Yelena RazgonyayevaGranada Hills$6K
- Nimaljeet TarangoSan Francisco$3K
- Alicia Terrado-LocquiaoVallejo$916
- Maria LeeSan Francisco$661
- Camille GabuyaFresno$461
- Cecile DizonSan Francisco$399
- Chad PetersonOakland$389
- Sreedevi WarrierTorrance$287
- Amy KramerSan Diego$145
- Julie BinionClovis$144
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.